Pharmacodynamic effects of continuously intravenously infused blinatumomab on T- and B-cell kinetics in the first treatment cycle of MRD+ ALL patients
| . | Mean ± SD . | Range . |
|---|---|---|
| T cells | ||
| Time, d | ||
| Time to T-cell nadir | 0.36 ± 0.24 | 0.06-1.09 |
| Time to 50% T-cell recovery | 3.13 ± 1.85 | 0.82-9.10 |
| Time to maximal T-cell increase | 17.57 ± 9.00 | 2.06-28.06 |
| T cells/μL | ||
| T-cell count at baseline | 532 ± 283 | 112-1364 |
| T-cell count at nadir | 36 ± 49 | 2-197 |
| Maximal T-cell count during treatment | 1013 ± 430 | 376-1954 |
| T-cell count at end of treatment | 737 ± 317 | 152-1410 |
| T-cell count after 1-wk recovery period | 825 ± 432 | 287-1599 |
| T cells, % | ||
| Maximal T-cell increase relative to baseline | 220 ± 123 | 93-547 |
| B cells | ||
| Time, d | ||
| Time to B-cell depletion | 2.18 ± 3.80 | 0.03-13.94 |
| B cells/μL | ||
| B-cell count at baseline | 75 ± 119 | 2-454 |
| B-cell count at end of treatment | 1 ± 1 | 0-4 |
| B-cell count after 1-wk recovery period | 1 ± 3 | 0-13 |
| . | Mean ± SD . | Range . |
|---|---|---|
| T cells | ||
| Time, d | ||
| Time to T-cell nadir | 0.36 ± 0.24 | 0.06-1.09 |
| Time to 50% T-cell recovery | 3.13 ± 1.85 | 0.82-9.10 |
| Time to maximal T-cell increase | 17.57 ± 9.00 | 2.06-28.06 |
| T cells/μL | ||
| T-cell count at baseline | 532 ± 283 | 112-1364 |
| T-cell count at nadir | 36 ± 49 | 2-197 |
| Maximal T-cell count during treatment | 1013 ± 430 | 376-1954 |
| T-cell count at end of treatment | 737 ± 317 | 152-1410 |
| T-cell count after 1-wk recovery period | 825 ± 432 | 287-1599 |
| T cells, % | ||
| Maximal T-cell increase relative to baseline | 220 ± 123 | 93-547 |
| B cells | ||
| Time, d | ||
| Time to B-cell depletion | 2.18 ± 3.80 | 0.03-13.94 |
| B cells/μL | ||
| B-cell count at baseline | 75 ± 119 | 2-454 |
| B-cell count at end of treatment | 1 ± 1 | 0-4 |
| B-cell count after 1-wk recovery period | 1 ± 3 | 0-13 |
Mean values ± SD and ranges for 20 evaluable patients are shown.
MRD indicates minimal residual disease; and ALL, acute lymphoblastic leukemia.